Episode Details

A pioneering lung cancer vaccine trial just began with Chris, a 68-year-old Merseyside woman, becoming the first patient globally to receive it. Engineered from her own tumor DNA, this personalized vaccine aims to revolutionize immunotherapy for advanced non-small cell lung cancer — the most common form. Doctors are thrilled, calling it a major leap forward. The treatment, delivered via a needle-free device, is faster, cheaper, and could soon be scaled across the NHS. Chris, motivated by her late daughter’s battle with breast cancer, hopes the vaccine will extend her life and help others. With just ten patients in the trial, researchers are optimistic it could transform outcomes for half of those with advanced lung cancer — and Chris is already eager to see if it works, with scans scheduled in six weeks.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/b435cc4cfd1646ec